Form 4 filings across 3 companies. Net figures count open-market buys and sales only. EDGAR profile ↗
Lifetime net: +$2M
Reported holding is the most recent post-transaction share count on a Table I row.
How quickly this filer reports. Section 16 allows two business days from the transaction.
1 of 11 filings we hold was filed after the two-business-day deadline. The furthest past the deadline was 16 business days late.
Counted in business days from the transaction date, or the deemed execution date where the filing reports one, excluding weekends and federal holidays. How this is measured
The 27 most recent Form 4 transactions.
| Jun 11 |
| CHRO |
| Channel Therapeutics Corp |
| PBUY |
| 35,445 |
| $27.80 |
| $985.5K |
| +88.9% |
| Open the original filing on SEC.gov |
| Jun 10 | PVLA | Palvella Therapeutics,… | AGRANT◆ | 3,000 | — | — | — | Open the original filing on SEC.gov |
| Mar 2 | LGND | Ligand Pharmaceuticals INC | AGRANT◆ | 50,058 | — | — | — | Open the original filing on SEC.gov |
| Mar 2 | LGND | Ligand Pharmaceuticals INC | AGRANT | 10,495 | — | — | +5.6% | Open the original filing on SEC.gov |
| Feb 15 | LGND | Ligand Pharmaceuticals INC | FTAX | 2,805 | $183.83 | $515.6K | -1.5% | Open the original filing on SEC.gov |
| Feb 15 | LGND | Ligand Pharmaceuticals INC | FTAX | 4,255 | $183.83 | $782.2K | -2.2% | Open the original filing on SEC.gov |
| Feb 15 | LGND | Ligand Pharmaceuticals INC | FTAX | 2,039 | $183.83 | $374.8K | -1.0% | Open the original filing on SEC.gov |
| Feb 14 | LGND | Ligand Pharmaceuticals INC | FTAX | 15,600 | $183.83 | $2.9M | -7.3% | Open the original filing on SEC.gov |
| Feb 14 | LGND | Ligand Pharmaceuticals INC | AGRANT | 39,644 | — | — | +22.8% | Open the original filing on SEC.gov |
| Feb 14 | LGND | Ligand Pharmaceuticals INC | FTAX | 8,178 | $183.83 | $1.5M | -4.5% | Open the original filing on SEC.gov |
| Feb 14 | LGND | Ligand Pharmaceuticals INC | AGRANT | 20,782 | — | — | +12.9% | Open the original filing on SEC.gov |
| Dec 4, 2025 | LGND | Ligand Pharmaceuticals INC | GGIFT | 130 | — | — | <0.1% | Open the original filing on SEC.gov |
| Jul 2, 2025 | CHRO | Channel Therapeutics Corp | AGRANT◆ | 58,230 | — | — | — | Open the original filing on SEC.gov |
| Jul 2, 2025 | CHRO | Channel Therapeutics Corp | AGRANT◆ | 19,108 | — | — | — | Open the original filing on SEC.gov |
| Jul 2, 2025 | CHRO | Channel Therapeutics Corp | AGRANT↺ | 19,108 | — | — | +92.0% | Open the original filing on SEC.gov |
| Jul 1, 2025 | CHRO | Channel Therapeutics Corp | JOTHER◆ | 31,278.68 | — | — | — | Open the original filing on SEC.gov |
| Jul 1, 2025 | CHRO | Channel Therapeutics Corp | CCONV◆ | 15,000 | — | — | — | Open the original filing on SEC.gov |
| Jul 1, 2025 | CHRO | Channel Therapeutics Corp | CCONV | 1.5M | $10.00 | $15M | — | Open the original filing on SEC.gov |
| Jun 30, 2025 | LGND | Ligand Pharmaceuticals INC | JOTHER | 233 | $91.08 | $21.2K | +0.1% | Open the original filing on SEC.gov |
| Jun 10, 2025 | PVLA | Palvella Therapeutics,… | AGRANT◆ | 12,350 | — | — | — | Open the original filing on SEC.gov |
| May 9, 2025 | LGND | Ligand Pharmaceuticals INC | PBUY | 5,523 | $105.67 | $583.6K | +3.5% | Open the original filing on SEC.gov |
| May 9, 2025 | LGND | Ligand Pharmaceuticals INC | PBUY | 2,307 | $104.53 | $241.1K | +1.5% | Open the original filing on SEC.gov |
| May 9, 2025 | LGND | Ligand Pharmaceuticals INC | PBUY | 1,680 | $104.57 | $175.7K | +1.1% | Open the original filing on SEC.gov |
| Nov 13, 2024 | CHRO | Channel Therapeutics Corp | AGRANT↺ | 4,961 | — | — | +31.4% | Open the original filing on SEC.gov |
| Jun 14, 2024 | CHRO | Channel Therapeutics Corp | AGRANT↺ | 12,900 | — | — | +442.2% | Open the original filing on SEC.gov |